EP-1403: Clinical outcome and toxicity of stereotactic ablative radiotherapy to centrally located tumors
Year: 2018
Type: conference-abstract
Abstract: S765ESTRO 37was a significant predictor for OS (median, 55.6 vs 24.5 months, p=0.04).Low PLR (≤ 153.1) was associated with longer PFS (45.2 vs 9.8 months, p=0.009).Low NLR (≤ 2.97) showed a trend toward better OS (45.5 vs 24.5 months) and PFS (18.7 vs 10.4 months) with no statistical difference (p=0.19,0.28). ConclusionPretreatment PLR and LMR could be prognostic markers for OS and PFS in patients with non-small cell lung cancer treated with chemoradiotherapy.
Source: Radiotherapy and Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,770
OpenAlex ID: W2808932611